Modulation of insulin sensitivity by insulin-degrading enzyme

Producción Científica

Insulin-degrading enzyme (IDE) is a highly conserved and ubiquitously expressed metalloprotease that degrades insulin and several other intermediate-size peptides. For many decades, IDE had been assumed to be involved primarily in hepatic insulin clearance, a key process that regulates availability of circulating insulin levels for peripheral tissues. Emerging evidence, however, suggests that IDE has several other important physiological functions relevant to glucose and insulin homeostasis, including the regulation of insulin secretion from pancreatic β-cells. Investigation of mice with tissue-specific genetic deletion of Ide in the liver and pancreatic β-cells (L-IDE-KO and B-IDE-KO mice, respectively) has revealed additional roles for IDE in the regulation of hepatic insulin action and sensitivity. In this review, we discuss current knowledge about IDE’s function as a regulator of insulin secretion and hepatic insulin sensitivity, both evaluating the classical view of IDE as an insulin protease and also exploring evidence for several non-proteolytic functions. Insulin proteostasis and insulin sensitivity have both been highlighted as targets controlling blood sugar levels in type 2 diabetes, so a clearer understanding the physiological functions of IDE in pancreas and liver could led to the development of novel therapeutics for the treatment of this disease.

Ministerio de Economía, Industria y Competitividad - (grant SAF2016-77871-C2-1-R; SAF2016-77871-C2-2-R)

Ministerio de Ciencia e Innovación - (grant PID2019-110496RB-C21; PID2019-110496RB-C22)

Fundación Europea para el Estudio de la Diabetes (Programa Europeo de Investigación de la Diabetes sobre nuevos objetivos para el tipo 2 Diabetes apoyada por MSD-2017)

US National Institutes of Health - (grant GM115617)

Fundación “la Caixa" - (grant LCF/PR/PR18/51130007)

Junta de Castilla y León y Fondo Social Europeo - ((ORDER EDU/574/2018 and ORDER EDU/556/2019)